OR WAIT 15 SECS
India’s emergence as a global healthtech and biotech innovation hub in the last decade, has chan...
In a move set to redefine non-invasive disease detection, Bengaluru-based Remidio, a global leader in artifici...
At a high-level meeting of the Department of Biotechnology, Union Minister of Science and Technology (S&T)...
Thermo Fisher Scientific has launched the One Lambda HybriType HLA Plus Typing Flex kit. This next-genera...
RIPPLE EFFECT of Cancer Drug Duty Cuts
To ease the financial strain on patients, the Union Budget 2025-26 has removed Basic Customs Duty (BCD) on 36 life-saving drugs used for cancer, rare diseases, and chronic conditions. This move is expected to make essential treatments more affordable by lowering overall costs. However, the real question remains: will this truly reduce the financial burden on patients? As prices decrease, what effects will this have on pharmaceutical companies, particularly in terms of sales and competition? Most importantly, how will local players adapt to these changes?
For Feedback, please email us at: communications@mmactiv.com
Sign up here to access BioSpectrum India Flip Book.
Sign up here to access BioSpectrum India Flip Book
